Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 26, Issue 2, 2011, Pages 584-591

  Isakova, Tamara ^a   Gutirrez, Orlando M ^a   Smith, Kelsey ^a   Epstein, Michael ^b   Keating, Leigh K ^b   Jppner, Harald ^b   Wolf, Myles ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

chronic kidney disease; FGF23; phosphate; phosphate binders

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS;

ADULT; ARTICLE; CALCIUM EXCRETION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; FACTORIAL DESIGN; HUMAN; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE URINE LEVEL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

AGED; CHELATING AGENTS; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; MIDDLE AGED; PHOSPHORUS COMPOUNDS; PHOSPHORUS, DIETARY; PILOT PROJECTS;

EID: 79551500014     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq419     Document Type: Article

References (26)

1. Saito H, Kusano K, KinosakiMet al. Human fibroblast growth factor- 23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278: 2206-2211
2. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435
3. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff Vet al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008
4. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor- 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
5. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279
6. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256
7. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149
8. Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21: 1187-1196
9. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524
10. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
11. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
12. Gutierrez OM, Mannstadt M, Isakova Tet al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
13. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339
14. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291
15. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
16. Calvo MS, Park YK. Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. J Nutr 1996; 126: 1168S-1180S
17. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
18. Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma f ibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517
19. Imel EA, Peacock M, Pitukcheewanont P et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006; 91: 2055-2061
20. Ito N, Fukumoto S, Takeuchi Y et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 2005; 23: 435-440
21. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585
22. Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda) 2009; 24: 17-25
23. Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69: 531-537
24. Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int 2006; 70: 1486-1494
25. Taylor EN, Curhan GC. Demographic, dietary, and urinary factors and 24-h urinary calcium excretion. Clin J Am Soc Nephrol 2009; 4: 1980-1987
26. Craver L, Marco MP, Martinez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007; 22: 1171-1176